We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ohr Pharmaceutical, Inc. (NASDAQCM: OHRP) to NeuBase Therapeutics, Inc. Under the terms of the transaction, Ohr shareholders will receive one share in the post-merger entity for each share of Ohr stock they own.
The Ohr merger investigation concerns whether the Board of Ohr breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether NeuBase Therapeutics, Inc. is underpaying for Ohr shares, thus unlawfully harming Ohr shareholders.
To receive more information, please fill out the form.